News | Heart Failure | January 10, 2017

BioVentrix Announces First Revivent TC Transcatheter Ventricular Enhancement Procedure in Germany

Procedure achieved 24 percent left ventricular volume reduction in ischemic heart failure patient

BioVentrix, Revivent TC Transcatheter Ventricular Enhancement System, LIVE procedure, first in Germany

January 10, 2017 — BioVentrix Inc. announced in December the first closed-chest Revivent TC TransCatheter Ventricular Enhancement System procedure in Germany since receiving CE mark certification. The Less Invasive Ventricular Enhancement (LIVE) procedure was performed by interventional cardiologists Christian Frerker, M.D. and Tobias Schmidt, M.D., and by cardiothoracic surgeon Ralf Bader, M.D., at Asklepios Klinik St. Georg in Hamburg, Germany.  The St. Georg Heart team is led by Prof. Dr. Karl-Heinz Kuck, who is also the chairman of the Department of Cardiology and Electrophysiology.

The physicians implanted two anchor pairs and achieved a left ventricular volume reduction of 24 percent, which is a significant improvement for a patient suffering from ischemic heart failure.  Left ventricular volume reduction is a common measure of cardiac performance that significantly impacts the short and long-term survival rates. By remodeling the LV to a more normal shape and size, the implant improves pumping efficiency, decreases wall stress and immediately reverses patient symptoms.

"We are pleased to be the first center in Germany to perform the Revivent TC procedure after CE mark certification," said Frerker.  "The Revivent TC procedure continues to show significant clinical benefits to patients who suffer from ischemic cardiomyopathy post-myocardial infarction. It's a viable solution when guideline directed medical therapy (GDMT) is not suitable," he continued.

"The 24 percent volume reduction should directly impact the heart's pumping efficiency, which is a positive outcome for ischemic patients. That will result in an improvement in the patient's quality of life," added Schmidt.  "This is the only minimally invasive technology which enables plication of scar tissue resulting in complete exclusion outside the LV cavity," he continued.

"The Revivent TC procedure alleviates wall stress by the reshaping of the left ventricle and allowing for the heart to operate as it was intended to going forward.  The immediate impact the Revivent TC procedure has on a patient is life-changing," added Bader.

For more information:

Related Content

Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Overlay Init